ArticleJournal of the American Society of Nephrology : JASN2018
Blood HER2 and Uromodulin as Causal Mediators of CKD.
Article in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.Breast cancer research and treatment · 2026Article
- Multiomics Mendelian randomization integrating pQTL, eQTL and mQTL data revealed BTN3A2 as a potential drug target for nephrolithiasis.Scientific reports · 2025Article
- Unveiling the role of transgelin as a prognostic and therapeutic target in kidney fibrosis via a proteomic approach.Experimental & molecular medicine · 2024Article
- Identification of novel therapeutic targets for chronic kidney disease and kidney function by integrating multi-omics proteome with transcriptome.Genome medicine · 2024Article
- Associations of diabetes, circulating protein biomarkers, and risk of pancreatic cancer.British journal of cancer · 2024Article
- Association between systemic immune-inflammation index and chronic kidney disease: A population-based study.PloS one · 2024Article
- From 'Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators.Current atherosclerosis reports · 2023Review
- Genome-wide studies reveal factors associated with circulating uromodulin and its relationships to complex diseases.JCI insight · 2022Article
- Role of uromodulin and complement activation in the progression of kidney disease.Oncology letters · 2021Article
- Causal Inference Methods to Integrate Omics and Complex Traits.Cold Spring Harbor perspectives in medicine · 2021Review
- High Level of Uromodulin Increases the Risk of Hypertension: A Mendelian Randomization Study.Frontiers in cardiovascular medicine · 2021Article
- Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: From current human evidence to future possibilities.Journal of diabetes investigation · 2020Review
- Association between serum HER2/ErbB2 levels and coronary artery disease: a case-control study.Journal of translational medicine · 2020Article
- Uromodulin in mineral metabolism.Current opinion in nephrology and hypertension · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
Many biomarkers have been epidemiologically linked with CKD; however, the possibility that such associations are due to reverse causation or confounding limits the utility of these biomarkers. To overcome this limitation, we used a Mendelian randomization (MR) approach to identify causal mediators of CKD. We performed MR by first identifying genetic determinants of 227 serum protein biomarkers assayed in 4147 participants of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial who had early or prediabetes, and assessing the effects of these biomarkers on CKD in the CKD genetics consortium (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.